Riverside Research Presented at the Innovations in Cancer Therapy and Response Monitoring Meeting

NEW YORK, NY – Riverside Research, a not-for-profit company chartered to advanced scientific research in the public interest and in support of the US government, presented at the Innovations in Cancer Therapy and Response Monitoring in Ontario, Canada on 16–17 November. The meeting brought together members of the industry and academia to discuss novel technologies related to cancer therapy and imaging.

Dr. Daniel Rohrbach represented the Frederic L. Lizzi Center for Biomedical Engineering at Riverside Research and presented two talks during the meeting. His first talk highlighted how 3D quantitative-ultrasound (QUS) methods show promise for better detection of lymph-node metastases and improved staging and treatment of cancer. Results of recent NIH-funded studies led by Dr. Ernest Feleppa, Director of the Lizzi Center, show that high-frequency QUS methods can potentially provide a reliable means of directing pathologists to otherwise missed micro-metastases in lymph nodes. Current studies extend these methods to lower ultrasound frequencies so that pathologists can identify cancerous lymph nodes in surgical specimens and surgeons can select cancerous lymph nodes preoperatively or intraoperatively for excision.

Dr. Rohrbach’s second talk discussed the use of high-frequency QUS to improve prostate-cancer imaging. The only current method for definitive diagnosis of prostate cancer is a core-needle biopsy guided by transrectal ultrasound. Previous NIH-funded prostate-imaging studies led by Dr. Feleppa showed that QUS can more reliably identify cancerous regions in the prostate than other imaging methods, and therefore, can improve the effectiveness of needle biopsies and enable focal treatment to be applied with confidence. Current studies funded by the New York State Department of Health, extend the earlier studies by investigating QUS-based imaging at higher ultrasound frequencies to provide a more sensitive and specific tool for guiding biopsies in targeting focal therapy to cancerous regions in the prostate.

Both talks not only presented the technical excellence of Riverside Research, but they also provided high-value solutions to very significant healthcare problems that affect millions of patients in the US and around the world.

To learn more about the meeting, visit www.radonc.utoronto.ca/event/innovations-toronto-2016-conference.